Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Valeant Pharma (VRX) Outperforms Amid Broad Weakness
May 11, 2017 9:54 AM EDTValeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness
... MoreStifel Comments On Valeant (VRX) Earnings
May 9, 2017 10:25 AM EDTStifel maintains Buy on Valeant Pharmaceuticals (NYSE: VRX) price target of $45.00.
Analyst Annabel Samimy stands out as one of two sell-side analysts who is bullish on the name with a Buy rating. Samimy expects headwinds to persist through the end of 2017 from managed... More
